XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2022

Summary of Significant Accounting Policies

Schedule of disaggregation of revenue by major source

The following table disaggregates our revenues by major markets for the three and nine months ended September 30, 2022 and 2021 (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Nine Months Ended

​

​

September 30,

​

September 30,

​

2022

2021

2022

2021

Biopharma/Pharma

​

$

48,570

​

$

46,001

​

$

143,309

​

$

133,878

Animal Health

​

9,629

​

​

8,261

​

​

25,985

​

​

25,655

Reproductive Medicine

​

​

2,265

​

​

2,431

​

​

7,625

​

​

6,635

Total revenues

​

$

60,464

​

$

56,693

​

$

176,919

​

$

166,168

Schedule of geographical revenues, by origin

Our geographical revenues, by origin, for the three and nine months ended September 30, 2022 and 2021, were as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Nine Months Ended

​

​

September 30,

​

September 30,

​

2022

2021

2022

2021

Americas

​

$

34,211

​

$

30,307

​

$

96,982

​

$

87,177

Europe, the Middle East, and Africa (EMEA)

​

16,000

​

​

14,382

​

​

49,041

​

​

43,632

Asia Pacific (APAC)

​

10,253

​

​

12,004

​

​

30,896

​

​

35,359

Total revenues

​

$

60,464

​

$

56,693

​

$

176,919

​

$

166,168

Schedule of net loss per share

The following shows the amounts used in computing net loss per share (in thousands except per share data):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Nine Months Ended

​

​

September 30,

​

September 30,

​

2022

2021

2022

2021

Net loss

​

$

(5,316)

​

$

(6,526)

​

$

(27,897)

​

$

(15,442)

Paid-in-kind dividend on Series C convertible preferred stock

​

(2,000)

​

​

(2,000)

​

​

(6,000)

​

​

(6,196)

Net loss attributable to common shareholders

​

$

(7,316)

​

$

(8,526)

​

$

(33,897)

​

$

(21,638)

Weighted average common shares issued and outstanding - basic and diluted

​

​

48,520,696

​

​

46,137,147

​

​

49,148,558

​

​

45,220,319

Basic and diluted net loss per share

​

$

(0.15)

​

$

(0.18)

​

$

(0.69)

​

$

(0.48)

​

Schedule of number of shares excluded from the computation of diluted loss per share

​

​	​	​	​	​	​	​	​	​
​	​	Three Months Ended			​	Nine Months Ended
​	​	September 30,			​	September 30,
​		2022		2021		2022		2021
Stock options		4,491,986	​	5,727,495	​	4,406,982	​	5,673,387
Restricted stock units	​	733,475	​	361,791	​	733,475	​	361,791
Series C convertible preferred stock	​	5,607,898	​	5,283,411	​	5,607,898	​	5,283,411
Conversion of 2026 Senior Notes	​	3,422,780	​	—	​	3,422,780	​	—
Conversion of 2025 Senior Notes		599,954	​	4,810,002	​	599,954	​	4,810,002
​		14,856,093	​	16,182,699	​	14,771,089	​	16,128,591

X

- References

No definition available.

+ Details

Name:	us-gaap_AccountingPoliciesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph a
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

+ Details

Name:	us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

+ Details

Name:	us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

+ Details

Name:	us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration